Compare
Oramed Pharmaceuticals Inc. vs Pliant Therapeutics, Inc. vs Siga Technologies Inc vs Damora Therapeutics, Inc.
| Latest fiscal year | Oramed Pharmaceuticals Inc. ORMPRevenue covers only part of its income (partial revenue) | Pliant Therapeutics, Inc. PLRX | Siga Technologies Inc SIGA | Damora Therapeutics, Inc. DMRA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $94.57M | n/a |
| Revenue growth (YoY) | n/a | n/a | -31.8% | n/a |
| Gross margin | n/a | n/a | 68.6% (computed) | n/a |
| Operating margin | n/a | n/a | 25.1% | n/a |
| Net margin | n/a | n/a | 24.6% | n/a |
| Net income | $64.05M | -$149.34M | $23.28M | -$209.84M |
| EPS (Diluted) | $1.50 | -$2.43 | $0.32 | $3.98 |
| Operating cash flow | -$9.14M | -$128.34M | $43.47M | -$6.73M |
| Free cash flow | -$9.15M | -$128.71M | n/a | n/a |
| Cash & equivalents | $45.95M | $45.45M | $154.97M | $257.62M |
| Total assets | $230.86M | $225.23M | $219.47M | $260.53M |
| Total liabilities | n/a | $44.02M | $20.65M | $20.15M |
| Shareholders' equity | $199.74M | $181.21M | $198.82M | $240.38M |
| Return on year-end equity | 32.1% | -82.4% | 11.7% | -87.3% |
| Shares outstanding | 39.28M | 61.45M | 71.61M | 1.60M |
Revenue, most recent five fiscal years
| Fiscal year | Oramed Pharmaceuticals Inc. | Pliant Therapeutics, Inc. | Siga Technologies Inc | Damora Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $94.57M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $138.72M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $1.58M Ended 2023-12-31 | $139.92M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $9.69M Ended 2022-12-31 | $110.78M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $7.57M Ended 2021-12-31 | $133.67M Ended 2021-12-31 | n/a |